441 related articles for article (PubMed ID: 24314025)
1. Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies.
Ebrahimi-Fakhari D; Saidi LJ; Wahlster L
Acta Neuropathol Commun; 2013 Dec; 1(1):79. PubMed ID: 24314025
[TBL] [Abstract][Full Text] [Related]
2. Molecular chaperones in Parkinson's disease--present and future.
Ebrahimi-Fakhari D; Wahlster L; McLean PJ
J Parkinsons Dis; 2011; 1(4):299-320. PubMed ID: 22279517
[TBL] [Abstract][Full Text] [Related]
3. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
Chaari A; Hoarau-Véchot J; Ladjimi M
Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
[TBL] [Abstract][Full Text] [Related]
4. Molecular chaperones and co-chaperones in Parkinson disease.
Dimant H; Ebrahimi-Fakhari D; McLean PJ
Neuroscientist; 2012 Dec; 18(6):589-601. PubMed ID: 22829394
[TBL] [Abstract][Full Text] [Related]
5. Aggregopathy in neurodegenerative diseases: mechanisms and therapeutic implication.
Dohm CP; Kermer P; Bähr M
Neurodegener Dis; 2008; 5(6):321-38. PubMed ID: 18309232
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of Parkinson's disease: emerging role of molecular chaperones.
Bandopadhyay R; de Belleroche J
Trends Mol Med; 2010 Jan; 16(1):27-36. PubMed ID: 20036196
[TBL] [Abstract][Full Text] [Related]
7. Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.
Kalia SK; Kalia LV; McLean PJ
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):741-53. PubMed ID: 20942788
[TBL] [Abstract][Full Text] [Related]
8. Protein degradation pathways in Parkinson's disease: curse or blessing.
Ebrahimi-Fakhari D; Wahlster L; McLean PJ
Acta Neuropathol; 2012 Aug; 124(2):153-72. PubMed ID: 22744791
[TBL] [Abstract][Full Text] [Related]
9. Molecular chaperones and Parkinson's disease.
Hu S; Tan J; Qin L; Lv L; Yan W; Zhang H; Tang B; Wang C
Neurobiol Dis; 2021 Dec; 160():105527. PubMed ID: 34626793
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 and Its Co-Chaperones in Neurodegenerative Diseases.
Bohush A; Bieganowski P; Filipek A
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31600883
[TBL] [Abstract][Full Text] [Related]
11. Targeting Chaperone/Co-Chaperone Interactions with Small Molecules: A Novel Approach to Tackle Neurodegenerative Diseases.
Wang L; Bergkvist L; Kumar R; Winblad B; Pavlov PF
Cells; 2021 Sep; 10(10):. PubMed ID: 34685574
[TBL] [Abstract][Full Text] [Related]
12. Collective roles of molecular chaperones in protein degradation pathways associated with neurodegenerative diseases.
Luo GR; Le WD
Curr Pharm Biotechnol; 2010 Feb; 11(2):180-7. PubMed ID: 20166963
[TBL] [Abstract][Full Text] [Related]
13. ɑ-Synuclein strains and the variable pathologies of synucleinopathies.
Peelaerts W; Baekelandt V
J Neurochem; 2016 Oct; 139 Suppl 1():256-274. PubMed ID: 26924014
[TBL] [Abstract][Full Text] [Related]
14. HSP70-HSP90 Chaperone Networking in Protein-Misfolding Disease.
Prodromou C; Aran-Guiu X; Oberoi J; Perna L; Chapple JP; van der Spuy J
Subcell Biochem; 2023; 101():389-425. PubMed ID: 36520314
[TBL] [Abstract][Full Text] [Related]
15. DNAJ Proteins in neurodegeneration: essential and protective factors.
Zarouchlioti C; Parfitt DA; Li W; Gittings LM; Cheetham ME
Philos Trans R Soc Lond B Biol Sci; 2018 Jan; 373(1738):. PubMed ID: 29203718
[TBL] [Abstract][Full Text] [Related]
16. Stable alpha-synuclein oligomers strongly inhibit chaperone activity of the Hsp70 system by weak interactions with J-domain co-chaperones.
Hinault MP; Cuendet AF; Mattoo RU; Mensi M; Dietler G; Lashuel HA; Goloubinoff P
J Biol Chem; 2010 Dec; 285(49):38173-82. PubMed ID: 20847048
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Role of Ubiquitin-Proteasome System in Parkinson's Disease.
Behl T; Kumar S; Althafar ZM; Sehgal A; Singh S; Sharma N; Badavath VN; Yadav S; Bhatia S; Al-Harrasi A; Almoshari Y; Almikhlafi MA; Bungau S
Mol Neurobiol; 2022 Jul; 59(7):4257-4273. PubMed ID: 35505049
[TBL] [Abstract][Full Text] [Related]
18. Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.
Sharma SK; Priya S
Cell Mol Life Sci; 2017 Feb; 74(4):617-629. PubMed ID: 27522545
[TBL] [Abstract][Full Text] [Related]
19. Molecular chaperones and associated cellular clearance mechanisms against toxic protein conformers in Parkinson's disease.
Hinault MP; Farina-Henriquez-Cuendet A; Goloubinoff P
Neurodegener Dis; 2011; 8(6):397-412. PubMed ID: 21411979
[TBL] [Abstract][Full Text] [Related]
20. Autophagy in Neurodegenerative Diseases: A Hunter for Aggregates.
Park H; Kang JH; Lee S
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
